Vera Therapeutics, Inc.

Equities

VERA

US92337R1014

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-22 pm EDT			5-day change	1st Jan Change
39.13 ^USD	+2.97%		-15.90%	+154.42%

Apr. 11	North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge	DJ
Apr. 10	Vera Therapeutics Shares Rise 9.9% After Alpine Acquisition	DJ

Vera Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022

May 16, 2022 at 07:32 am EDT

Vera Therapeutics, Inc. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported net loss was USD 17.09 million compared to USD 4.71 million a year ago. Basic loss per share from continuing operations was USD 0.71 compared to USD 12.23 a year ago. Diluted loss per share from continuing operations was USD 0.71 compared to USD 12.23 a year ago.

Latest news about Vera Therapeutics, Inc.

North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge	Apr. 11	DJ
Vera Therapeutics Shares Rise 9.9% After Alpine Acquisition	Apr. 10	DJ
Certain Restricted Stock Units of Vera Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 29-MAR-2024.	Mar. 28	CI
Certain Stock Options of Vera Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 29-MAR-2024.	Mar. 28	CI
Certain Class A common stock of Vera Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 29-MAR-2024.	Mar. 28	CI
Wedbush Raises Vera Therapeutics' Price Target to $34 From $21 After Model Update, Maintains Neutral rating	Mar. 21	MT
Sector Update: Health Care Stocks Steady Premarket Wednesday	Mar. 20	MT
Vera Therapeutics' 2023 Loss Narrows	Mar. 20	MT
Vera Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 20	CI
Certain Restricted Stock Units of Vera Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 14-MAR-2024.	Mar. 13	CI
Certain Stock Options of Vera Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 14-MAR-2024.	Mar. 13	CI
Certain Class A common stock of Vera Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 14-MAR-2024.	Mar. 13	CI
Top Premarket Decliners	Feb. 28	MT
Vera Therapeutics Insider Bought Shares Worth $4,999,990, According to a Recent SEC Filing	Feb. 01	MT
Vera Therapeutics Prices Upsized $250 Million Public Offering of Class A Shares	Jan. 30	MT
Sector Update: Health Care Stocks Steady Premarket Monday	Jan. 29	MT
Vera Therapeutics to Offer $200.0 Million of Class A Common Stock	Jan. 29	MT
North American Morning Briefing : Cautious Start -2-	Jan. 29	DJ
Top Midday Gainers	Jan. 26	MT
Oppenheimer Raises Vera Therapeutics Price Target to $34 From $26, Maintains Outperform Rating	Jan. 26	MT
Raymond James Upgrades Vera Therapeutics to Strong Buy From Outperform, Raises PT to $37 From $29	Jan. 26	MT
Wedbush Raises Vera Therapeutics' Price Target to $21 From $16, Keeps Neutral Rating	Jan. 26	MT
Sector Update: Health Care Stocks Softer Late Afternoon	Jan. 25	MT
Top Midday Gainers	Jan. 25	MT
Sector Update: Health Care Stocks Slipping Thursday Afternoon	Jan. 25	MT

Chart Vera Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Vera Therapeutics, Inc. is a late-stage biotechnology company. The Company is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Its product candidate, atacicept, is a self-administered fusion protein that blocks both a B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL) which stimulates B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases. The Company is also engaged in developing MAU868, a monoclonal antibody designed to neutralize infection with BK Virus, a polyomavirus that can have devastating consequences in certain settings such as kidney transplants. The Company is conducting a randomized, double-blind, placebo-controlled Phase 3 clinical trial in IgAN, which it refers to as ORIGIN 3, and completing the open label extension of its Phase 2b clinical trial in IgAN, which it refers to as ORIGIN 2b.

Sector

Biotechnology & Medical Research

Calendar

2024-05-15 - Annual General Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

39.13 USD

Average target price

55.8 USD

Spread / Average Target

+42.60%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
VERA THERAPEUTICS, INC.	+154.42%	2.13B
IQVIA HOLDINGS INC.	-0.02%	42.11B
LONZA GROUP AG	+45.94%	40.08B
MODERNA, INC.	+5.04%	40B
CELLTRION, INC.	-11.32%	26.87B
ICON PUBLIC LIMITED COMPANY	+5.25%	24.58B
ALNYLAM PHARMACEUTICALS, INC.	-23.83%	18.44B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.62%	11.94B
MEDPACE HOLDINGS, INC.	+22.75%	11.66B
UNITED THERAPEUTICS CORPORATION	+6.44%	11.01B

Other Biotechnology & Medical Research